Researchers review progress on cancer vaccines
Johns Hopkins Medicine
For more than three decades, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center researchers have pursued an ambitious idea: that vaccines could train the immune system to recognize and fight cancer. Now, a landmark phase III clinical trial of a personalized melanoma vaccine shows that this approach can improve outcomes for patients.
Johns Hopkins Kimmel Cancer Center was among the clinical centers that
participated in the multicenter study with William
Sharfman, M.D., Mary Jo Rogers Professor of Cancer Immunology and Melanoma
Research, serving as the Johns Hopkins Medicine principal investigator.
“Vaccines have been among the most transformative advances
in modern medicine,” says Mark
Yarchoan, M.D., associate professor of oncology, in an editorial published
Nov. 11 in the New
England Journal of Medicine, accompanying the melanoma trial results.
“However, until now, efforts to develop vaccines that directly target
established cancers have been largely unsuccessful.”
The clinical trial results mark a turning point for a field
shaped by decades of fundamental discoveries and many clinical setbacks. Among
its pioneers is Elizabeth
Jaffee, M.D., the Dana and Albert “Cubby” Broccoli Professor of Oncology
and deputy director of the Johns Hopkins Kimmel Cancer Center, whose work
helped establish therapeutic cancer vaccination as a promising strategy to
fight cancer.
“For years, we believed we could teach the immune system to
recognize cancer, but we didn’t yet have all of the tools to make this work in
patients,” says Jaffee, who is also co-director of the Kimmel Cancer Center’s Skip
Viragh Center for Pancreatic Cancer and associate director of its Bloomberg~Kimmel
Institute for Cancer Immunotherapy. “These results reflect decades of work
by many scientists and patients who kept pushing the field forward, even when
early clinical trials were disappointing.”
In the late 1980s, Jaffee and other Johns Hopkins Sidney Kimmel Comprehensive Cancer Center immunologists helped pioneer therapeutic cancer vaccines. Jaffee and Daniel Laheru, M.D., the Ian T. MacMillan Professor in Clinical Pancreatic Cancer and co-director of the Skip Viragh Center for Pancreatic Cancer, brought the approach into early clinical trials for pancreatic cancer. Their GVAX vaccine used genetically modified tumor cells to stimulate an immune response against cancer. Later studies demonstrated that vaccination could generate organized clusters of immune cells within pancreatic tumors, long considered among the hardest cancers for the immune system to attack.
Other breakthroughs at Johns Hopkins Medicine helped
explain why cancer vaccines might work better when combined with immunotherapy.
Research by Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute
for Cancer Immunotherapy scientists, including Drew
Pardoll, M.D., Ph.D., Suzanne
Topalian, M.D., and Julie
Brahmer, M.D., helped advance PD-1 checkpoint inhibitors, drugs that
release the brakes on the immune system and are now being combined with cancer
vaccines.
At the same time, advances in cancer genetics and immunology
helped identify what cancer-fighting T cells should attack. Building on
pioneering cancer genetics research at the Ludwig
Center at Johns Hopkins, Bert
Vogelstein, M.D., Clayton Professor of Oncology and Howard Hughes Medical
Institute investigator, and Kenneth
Kinzler, Ph.D., Barry Family Professor of Oncology, helped demonstrate the
importance of genetic mutations in determining which cancers respond to
immunotherapy. Studies led by Dung Le,
M.D., Bloomberg~Kimmel Professor of Cancer Immunotherapy, and former Kimmel
Cancer Center faculty member Luis Diaz, M.D., linked defects in DNA mismatch
repair (DNA copying errors that cause high rates of mutations) to responses to
PD-1 blockade. Subsequent research at the Johns Hopkins Kimmel Cancer Center
showed that PD-1 therapy can expand T cells that recognize mutation-associated
neoantigens, proteins created by mutations found in cancer cells but not
healthy tissue.
Together, these discoveries helped establish the rationale
behind today’s personalized cancer vaccines: identify the distinctive mutations
in a patient’s tumor, vaccinate against them to stimulate cancer-specific T
cells, and use checkpoint blockade to help those immune cells remain active. In
2016, the Bloomberg~Kimmel Institute for Cancer Immunotherapy brought
researchers working on vaccines, immunotherapies, tumor genetics and clinical
trials into closer collaboration.
Johns Hopkins Kimmel Cancer Center researchers are already
developing cancer vaccines that aim to extend this approach to other tumor
types and earlier stages of disease. In a 2024
study led by Yarchoan, a personalized vaccine combined with the
immunotherapy drug pembrolizumab showed encouraging activity in hepatocellular
carcinoma, the most common form of liver cancer. A separate Johns Hopkins-led vaccine
trial conducted by Yarchoan and Marina
Baretti, M.D., the Jiasheng Professor in Hepato-Biliary Cancer Research,
showed responses in fibrolamellar carcinoma, a rare liver cancer that affects
adolescents and young adults.
Building on decades of pioneering cancer vaccine research,
Jaffee and Neeha
Zaidi, M.D., associate professor of oncology, are leading clinical studies
of an experimental vaccine targeting mutations in KRAS, a gene altered in more
than 90% of pancreatic cancers. KRAS mutations can occur a decade or more
before pancreatic cancer develops, so they offer an opportunity to train the
immune system to recognize and attack abnormal cells before they become cancer.
In a recent study involving 20 people
at elevated risk for pancreatic cancer, the vaccine was safe and generated
significant immune responses in 90% of participants, with cancer-fighting
immune cells detectable for up to two years. None developed pancreatic cancer
during the follow-up period, although larger studies with longer follow-up are
needed to determine whether the vaccine can prevent the disease.
Additional studies are exploring whether the vaccine can
prevent certain pancreatic cysts from progressing to cancer and whether
combining the vaccine with other immunotherapies can improve treatment for
patients who already have pancreatic cancer.
Yarchoan says the emerging evidence suggests cancer vaccines may ultimately have applications across multiple cancer types, but realizing their full potential will require ambitious clinical trials and sustained research investment.
.jpeg)